Revelation Biosciences, Inc.REVB

Revelation Biosciences Inc. (NASDAQ: REVB) spent the last two weeks of July reminding everyone that its board is armed with a shareholder rights plan adopted on July 10, 2026, complete with a 15% trigger and a $30 strike price-corporate body armour for a company whose flagship asset, GEMINI, is still in clinical development and whose latest 10-Q shows a three-month loss of $3 million.

The poison pill arrives just as Revelation reports it has inked an FDA agreement on the Gemini approval pathway for acute kidney injury, and has kicked off GMP manufacturing of both Gemini and placebo to support later-stage trials. The juxtaposition is hard to miss: a board that can deploy a rights plan faster than it can turn preclinical science into revenue, while leaning on FDA pathway clarity as its nearest thing to a near-term catalyst.

The 10-Q for the three months ended March 31, 2026 shows $15 million in total assets, $2.1 million in liabilities, and a net cash outflow from operations of $3.2 million. Research and development expense hit $1.4 million, while capitalised cash stood at $14.1 million. Diluted loss per share was $2.71 on 3.2 million weighted average shares outstanding. The company also paid $71,879 for plant, property, and equipment-about the cost of a single high-end bioreactor, which is roughly the scale of Revelation’s physical footprint today.

For context on the product side, the company’s own newsroom confirms it has reached agreement with the FDA on the Gemini approval pathway and initiated GMP manufacturing, but it has not yet disclosed any revenue, customer agreements, or commercial-scale supply deals. The press pages tout progress, while the filings show the cash runway is the real story.

Chart context: the SEC EDGAR companyfacts JSON and submissions JSON are public rails, and the company’s investor site hosts product graphics, but none of these materials supply price levels, trading volumes, or market-cap data. Without those inputs, the chart is a blank canvas waiting for the market to fill it. (source: REVB SEC EDGAR filing index, https://www.sec.gov/edgar/browse/?CIK=1810560; REVB SEC submissions JSON, https://data.sec.gov/submissions/CIK0001810560.json; REVB SEC companyfacts JSON, https://data.sec.gov/api/xbrl/companyfacts/CIK0001810560.json; Revelation Biosciences Announces Financial Results For the Three Months Ended March 31, 2026 - Revelation BioSciences, https://www.revbiosciences.com/press-releases/dd3w8r56vnmdn6ri4itai4k0ron2iv)